Skip to main content
Top

Drugs

Issue 15/2018

Content (11 Articles)

Targeted Therapies for Autoimmune Bullous Diseases: Current Status

  • Leading Article

Kyle T. Amber, Roberto Maglie, Farzan Solimani, Rüdiger Eming, Michael Hertl

Cardiovascular Safety of Antihyperglycemic Agents: “Do Good or Do No Harm”

  • Review Article

Antonis A. Manolis, Theodora A. Manolis, Antonis S. Manolis

Antibiotics and Cure Rates in Childhood Febrile Urinary Tract Infections in Clinical Trials: A Systematic Review and Meta-analysis

  • Systematic Review

Konstantinos Vazouras, Romain Basmaci, Julia Bielicki, Laura Folgori, Theoklis Zaoutis, Mike Sharland, Yingfen Hsia

Sodium Zirconium Cyclosilicate: A Review in Hyperkalaemia

  • Open Access
  • Adis Drug Evaluation

Sheridan M. Hoy

Patisiran: First Global Approval

  • AdisInsight Report

Sheridan M. Hoy

Lanadelumab: First Global Approval

  • AdisInsight Report

Yahiya Y. Syed

Caplacizumab: First Global Approval

  • Open Access
  • AdisInsight Report

Sean Duggan

Doravirine: First Global Approval

  • AdisInsight Report

Emma D. Deeks

Correction to: Delafloxacin: First Global Approval

  • Open Access
  • Correction

Anthony Markham

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images